| (USD) | Sep 2023 | Q/Q |
|---|---|---|
| Revenue | 17.9MM | +2% |
| Gross Profit | 11.8MM | -8% |
| Cost Of Revenue | 6.1MM | +27% |
| Operating Income | -8.9MM | +21% |
| Operating Expenses | 20.6MM | +3% |
| Net Income | -9.4MM | +92% |
| R&D | 2.2MM | -9% |
| G&A | 6.3MM | +2% |
| Marketing | 12.1MM | +5% |
| Amortization | 500K | - |
| Interest Expense | 1.2MM | +3% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Lack of early symptom improvement is not predictive of final responder statusMALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the publication of significant clinical findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation, the premier journal in t
Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.
MALVERN, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 135,000 shares of the Company’s common stock (RSUs) to eleven new non-executive employees. In accordance with NASDAQ Listing Rule
William Blair analysts called the clearance a positive surprise, explaining that the FDA has denied several therapies in the patient population.
NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and olderMALVERN, Pa., March 25, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced clearance from the U.S. Food and Drug Administration (FDA) for NeuroStar Advanced Therapy for use as an adjunct for the treatment
The collaboration between Neuronetics (STIM) and TCN holds particular significance in the realm of treatment-resistant depression.
Strong Utilization Trends and Operational Highlights Drive Growth
Neuronetics, Inc. (NASDAQ:STIM) Q4 2023 Earnings Call Transcript March 5, 2024 Neuronetics, Inc. beats earnings expectations. Reported EPS is $-0.19, expectations were $-0.26. STIM isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing by. […]
MALVERN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced an expanded commercial partnership with Transformations Care Network ("TCN"), one of the nation's largest mental health care providers. Under the new agreement, Neuronetics will be the exclusive supplier of new transcranial magnetic sti
Neuronetics ( NASDAQ:STIM ) Full Year 2023 Results Key Financial Results Revenue: US$71.3m (up 9.4% from FY 2022). Net...